Federated Hermes
BCRX icon

Federated Hermes’s BioCryst Pharmaceuticals BCRX Stock Holding History

Federated Hermes’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73K Sell
7,296
-299,168
-98% -$2.71M ﹤0.01% 1656
2026
Q1 		$2.92M Buy
306,464
+13,614
+5% +$106K ﹤0.01% 889
2025
Q4 		$2.28M Buy
292,850
+27,345
+10% +$198K ﹤0.01% 935
2025
Q3 		$2.02M Sell
265,505
-32,696
-11% -$272K ﹤0.01% 929
2025
Q2 		$2.67M Buy
298,201
+113,297
+61% +$1.06M 0.01% 868
2025
Q1 		$1.39M Buy
184,904
+16,947
+10% +$137K ﹤0.01% 1026
2024
Q4 		$1.26M Buy
167,957
+56,930
+51% +$432K ﹤0.01% 1044
2024
Q3 		$844K Buy
+111,027
New +$844K ﹤0.01% 1180
2022
Q2 		– Sell
-348
Closed -$6K – 2149
2022
Q1 		$6K Sell
348
-47,893
-99% -$768K ﹤0.01% 1933
2021
Q4 		$668K Sell
48,241
-819,896
-94% -$10.9M ﹤0.01% 1402
2021
Q3 		$12.5M Buy
868,137
+121,166
+16% +$1.91M 0.02% 592
2021
Q2 		$11.8M Buy
746,971
+722,057
+2,898% +$9.81M 0.02% 603
2021
Q1 		$253K Buy
24,914
+24,750
+15,091% +$255K ﹤0.01% 1670
2020
Q4 		$1K Buy
+164
New +$845 ﹤0.01% 2157
2019
Q4 		– Sell
-331,172
Closed -$949K – 2212
2019
Q3 		$949K Sell
331,172
-277,144
-46% -$862K ﹤0.01% 1289
2019
Q2 		$2.31M Sell
608,316
-171,090
-22% -$1.03M 0.01% 1018
2019
Q1 		$6.34M Buy
779,406
+343,269
+79% +$2.94M 0.02% 712
2018
Q4 		$3.52M Buy
436,137
+434,756
+31,481% +$3.38M 0.01% 841
2018
Q3 		$11K Buy
+1,381
New +$9.28K ﹤0.01% 1938
2017
Q3 		– Sell
-69,320
Closed -$385K – 2139
2017
Q2 		$385K Sell
69,320
-182,740
-72% -$1.11M ﹤0.01% 1438
2017
Q1 		$2.12M Buy
252,060
+168,225
+201% +$1.17M 0.01% 887
2016
Q4 		$531K Buy
83,835
+2,983
+4% +$15.5K ﹤0.01% 1290
2016
Q3 		$357K Sell
80,852
-23,722
-23% -$94.8K ﹤0.01% 1373
2016
Q2 		$297K Buy
+104,574
New +$325K ﹤0.01% 1405
2016
Q1 		– Sell
-1,000
Closed -$10K – 2102
2015
Q4 		$10K Buy
+1,000
New +$9.94K ﹤0.01% 1792

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Federated Hermes's BCRX Position: Q2 2026 in Review

Federated Hermes reduced its BioCryst Pharmaceuticals (BCRX) stake by 98% in Q2 2026, selling an estimated $2.71M and leaving 7,296 shares worth $73K. The position accounts for ﹤0.01% of the portfolio, ranked #1656.

Federated Hermes first reported a position in BCRX in Q4 2015 and has held it in 25 quarters since. The position peaked at $12.5M in Q3 2021. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Federated Hermes held 7,296 shares of BioCryst Pharmaceuticals worth $73K as of Q2 2026.
  • Federated Hermes sold 299,168 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $2.71M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1656 holding.
  • Federated Hermes first reported a position in BioCryst Pharmaceuticals in Q4 2015 and has held it in 25 quarters since.
  • Federated Hermes's BioCryst Pharmaceuticals position peaked at $12.5M in Q3 2021.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.